Latest news

• MSD invests in FKD Therapies

  MSD has taken an equity stake in the Finland based company, FKD Therapies, owned by former CEO of Ark Therapeutics Nigel Parker. ... FKD Therapies, which has reserves of $16m, is a company started by Nigel Parker, the former chief executive of Ark

• Ark files documentation on Cerepro

  Ark Therapeutics Group has requested re-examination of the marketing approval application for its brain cancer drug, Cerepro, from the EMA. ... Ark Therapeutics Group has filed documentation with the European Medicines Agency (EMA) in relation to its

• Close but no cigar

  A number of promising candidates include Introgen's contusugene ladenovec (ADVEXIN), an adenoviral p53 gene therapy, and Ark Therapeutics' sitimagene ceradenovec (Cerepro). ... Another candidate under regulatory review is sitimagene ceradenovec (Cerepro),

• R&D news in brief

  Ark reveals new R&D head. David Eckland has been appointed head of research and development at Ark Therapeutics, the company has revealed. ... Ark Therapeutics is a spin-out biotech company from University College London and successfully floated on the

• R&D news in brief

  to scientists working in Finland for UK biotech firm Ark Therapeutics. ... While, until now, gene therapy delivery has relied on the insertion of DNA almost at random into human chromosomes, Ark said it was using targeting molecules, known as integrase